Identification

Name
Furosemide
Accession Number
DB00695  (APRD00608, DB07799)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]

Structure
Thumb
Synonyms
  • 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
  • 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
  • 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
  • 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
  • Frusemide
  • Furosemid
  • Furosemida
  • Furosemide
  • Furosemidu
  • Furosemidum
  • Lasix (tn)
External IDs
LB-502 / NSC-269420
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Furosemide Tab 20mgTablet20 mgOralApotex Corporation1977-12-31Not applicableCanada
Apo Furosemide Tab 40mgTablet40 mgOralApotex Corporation1976-12-31Not applicableCanada
Apo Furosemide Tab 80mgTablet80 mgOralApotex Corporation1986-12-31Not applicableCanada
FuosemideTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1983-11-10Not applicableUs
FurosemideTablet20 mg/1OralA S Medication Solutions1981-10-192017-06-20Us
FurosemideTablet40 mg/1OralCardinal Health2010-10-12Not applicableUs
FurosemideInjection, solution10 mg/mLIntramuscular; IntravenousCardinal Health2013-11-19Not applicableUs
FurosemideTablet20 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2017-08-11Not applicableUs
FurosemideTablet80 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1981-10-19Not applicableUs
FurosemideTablet40 mg/1OralAphena Pharma Solutions Tennessee, Inc.1981-08-27Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Active-Medicated specimen collection kitKitN.O.R.T.H., Inc.2013-10-31Not applicableUs
Ava-furosemideTablet20 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-furosemideTablet80 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-furosemideTablet40 mgOralAvanstra Inc2011-08-112014-08-21Canada
Bio-furosemideTablet40 mgOralBiomed Pharma2003-04-11Not applicableCanada
Bio-furosemideTablet20 mgOralBiomed Pharma2003-04-11Not applicableCanada
Diascreen 12-Panel Medicated Collection SystemKitIt3 Medical Llc2016-07-27Not applicableUs
Dom-furosemideTablet20 mgOralBiomed Pharma2003-10-142013-08-02Canada
Dom-furosemideTablet40 mgOralBiomed Pharma2003-10-142013-08-02Canada
FurosemideTablet40 mg/1OralProficient Rx LP2009-01-29Not applicableUs
International/Other Brands
Diurapid (Mibe Jena) / Diurin (Mylan) / Diurmessel (Biomep) / Eutensin (Sanofi) / Frumex / Frusenex / Frusol (Rosemont) / Furo-Puren (Actavis) / Seguril (Sanofi)
Categories
UNII
7LXU5N7ZO5
CAS number
54-31-9
Weight
Average: 330.744
Monoisotopic: 330.007719869
Chemical Formula
C12H11ClN2O5S
InChI Key
ZZUFCTLCJUWOSV-UHFFFAOYSA-N
InChI
InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
IUPAC Name
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
SMILES
NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O

Pharmacology

Indication

For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.

Associated Conditions
Pharmacodynamics

Furosemide, a sulfonamide-type loop diuretic structurally related to bumetanide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome.

Mechanism of action

Furosemide, a loop diuretic, inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic.

TargetActionsOrganism
ASolute carrier family 12 member 1
inhibitor
Human
UCarbonic anhydrase 2Not AvailableHuman
Absorption

60% absorbed in patients with normal renal function

Volume of distribution
Not Available
Protein binding

95% bound to plasma proteins

Metabolism

Only a small amount is hepatically metabolized to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.

Route of elimination

Furosemide is excreted in urine. Significantly more furosemide is excreted in urine following the I.V. injection than after the tablet or oral solution.

Half life

2 hours

Clearance
Not Available
Toxicity

Profound diuresis may cause fluid and electrolyte depletion. Excessive dehydration and potassium depletion may occur. Excessive diuresis may cause rapid weight loss, orthostatic hypotension or acute hypotensive episodes. May also cause tinnitus, reversible or permanent hearing loss or reversible deafness.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Furosemide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Furosemide.Experimental
(4R)-limoneneThe therapeutic efficacy of Furosemide can be decreased when used in combination with (4R)-limonene.Investigational
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Furosemide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Furosemide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Furosemide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Furosemide.Experimental, Illicit
AbediterolAbediterol may increase the hypokalemic activities of Furosemide.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Furosemide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Furosemide is combined with Acebutolol.Approved, Investigational
AceclofenacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinFurosemide may increase the excretion rate of Acemetacin which could result in a lower serum level and potentially a reduction in efficacy.Approved, Experimental, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Furosemide.Approved, Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Furosemide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Furosemide.Experimental, Investigational
AlclofenacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Furosemide.Approved
AlcuroniumFurosemide may decrease the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Furosemide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Furosemide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Furosemide.Approved, Illicit
AliskirenThe serum concentration of Furosemide can be decreased when it is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Furosemide.Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Furosemide is combined with Allopurinol.Approved
AlminoprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Furosemide.Approved
AloxiprinThe therapeutic efficacy of Furosemide can be decreased when used in combination with Aloxiprin.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Furosemide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Furosemide.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Furosemide.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Furosemide.Approved, Investigational
AmikacinThe serum concentration of Amikacin can be increased when it is combined with Furosemide.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Furosemide.Approved
Aminosalicylic AcidThe therapeutic efficacy of Furosemide can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Furosemide.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Furosemide.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Furosemide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Furosemide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Furosemide is combined with Amyl Nitrite.Approved
AndrographolideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Furosemide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Furosemide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Furosemide.Investigational
AnisodamineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Antipyrine.Approved, Investigational
ApocyninThe therapeutic efficacy of Furosemide can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Furosemide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Furosemide is combined with Apraclonidine.Approved
ApramycinThe serum concentration of Apramycin can be increased when it is combined with Furosemide.Experimental, Vet Approved
ApremilastThe therapeutic efficacy of Furosemide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbekacinThe serum concentration of Arbekacin can be increased when it is combined with Furosemide.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Furosemide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Furosemide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Furosemide.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Furosemide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Furosemide.Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Furosemide.Approved
AtracuriumFurosemide may decrease the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateFurosemide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Furosemide is combined with Azilsartan medoxomil.Approved, Investigational
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Furosemide.Investigational
BalsalazideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Furosemide.Experimental
BarbitalBarbital may increase the hypotensive activities of Furosemide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Furosemide.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Furosemide.Approved, Investigational
BekanamycinThe serum concentration of Bekanamycin can be increased when it is combined with Furosemide.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Furosemide.Investigational
BenazeprilFurosemide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Furosemide.Approved
BenorilateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Benzydamine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Furosemide.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Furosemide.Approved, Investigational
BevoniumThe therapeutic efficacy of Furosemide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Furosemide.Experimental, Illicit, Withdrawn
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Furosemide.Approved
BitolterolBitolterol may increase the hypokalemic activities of Furosemide.Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Furosemide.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Furosemide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Furosemide.Approved
BromfenacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Furosemide.Approved, Investigational
BucillamineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Furosemide.Approved
BufexamacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Bufexamac.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Furosemide.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Furosemide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Furosemide.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furosemide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Furosemide.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of hypotension can be increased when Canagliflozin is combined with Furosemide.Approved
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Furosemide.Approved
CandoxatrilFurosemide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilFurosemide may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumThe therapeutic efficacy of Furosemide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Furosemide.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Furosemide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Furosemide.Illicit, Investigational, Vet Approved
CarprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Furosemide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Furosemide is combined with Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Furosemide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Furosemide.Approved, Investigational
Chloral hydrateThe risk or severity of adverse effects can be increased when Furosemide is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloroquineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Furosemide is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Furosemide.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Furosemide.Approved, Investigational
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Furosemide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Furosemide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Furosemide.Experimental
CilazaprilFurosemide may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Furosemide.Approved, Investigational
CisatracuriumFurosemide may decrease the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe risk or severity of ototoxicity and nephrotoxicity can be increased when Furosemide is combined with Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Furosemide.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Clevidipine.Approved, Investigational
ClobetasolClobetasol may increase the hypokalemic activities of Furosemide.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Furosemide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Furosemide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Furosemide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Furosemide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Furosemide.Approved, Investigational, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Furosemide.Approved
ClonixinThe therapeutic efficacy of Furosemide can be decreased when used in combination with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Furosemide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Furosemide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Furosemide.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Furosemide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Furosemide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Furosemide.Approved, Investigational
CurcuminThe therapeutic efficacy of Furosemide can be decreased when used in combination with Curcumin.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Furosemide.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be increased when Furosemide is combined with Cymarin.Experimental
DapagliflozinThe risk or severity of adverse effects can be increased when Furosemide is combined with Dapagliflozin.Approved
DecamethoniumFurosemide may decrease the neuromuscular blocking activities of Decamethonium.Approved
DeflazacortDeflazacort may increase the hypokalemic activities of Furosemide.Approved, Investigational
DelaprilFurosemide may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Furosemide.Investigational
DersalazineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Furosemide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Furosemide is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Furosemide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Furosemide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Furosemide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Furosemide.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Furosemide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Furosemide.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Furosemide.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Furosemide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Furosemide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Furosemide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Furosemide.Approved, Investigational
DibekacinThe serum concentration of Dibekacin can be increased when it is combined with Furosemide.Experimental
DiclofenacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Diclofenamide.Approved, Investigational
DifenpiramideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Furosemide.Approved
DiflunisalThe therapeutic efficacy of Furosemide can be decreased when used in combination with Diflunisal.Approved, Investigational
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Furosemide.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hypokalemic activities of Furosemide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Furosemide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Furosemide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Furosemide.Experimental, Illicit
DihydrostreptomycinThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Furosemide.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Furosemide.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Furosemide is combined with Dinutuximab.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furosemide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Furosemide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Furosemide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Furosemide.Approved
DofetilideThe risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Furosemide is combined with Dofetilide.Approved, Investigational
Domoic AcidFurosemide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chlorideFurosemide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Furosemide.Approved
DoxofyllineDoxofylline may increase the hypokalemic activities of Furosemide.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Furosemide.Experimental
DroxicamThe therapeutic efficacy of Furosemide can be decreased when used in combination with Droxicam.Withdrawn
DroxidopaDroxidopa may increase the hypokalemic activities of Furosemide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Furosemide.Approved, Investigational
DuloxetineFurosemide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Furosemide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Furosemide can be decreased when used in combination with E-6201.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Furosemide.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Furosemide is combined with Empagliflozin.Approved
EnalaprilFurosemide may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatFurosemide may increase the hypotensive activities of Enalaprilat.Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Furosemide.Experimental
EphedraEphedra may increase the hypokalemic activities of Furosemide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Furosemide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Furosemide is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Furosemide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Furosemide.Experimental
EquilinEquilin may increase the hypokalemic activities of Furosemide.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Furosemide.Approved
EstroneEstrone may increase the hypokalemic activities of Furosemide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Furosemide.Approved
Etacrynic acidFurosemide may increase the ototoxic activities of Etacrynic acid.Approved, Investigational
EtafedrineEtafedrine may increase the hypokalemic activities of Furosemide.Approved
EtanerceptThe therapeutic efficacy of Furosemide can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Ethenzamide.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Furosemide.Approved, Illicit
EtodolacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Furosemide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Furosemide.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Furosemide can be decreased when used in combination with Evening primrose oil.Investigational, Nutraceutical
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Furosemide.Approved, Investigational
ExisulindThe therapeutic efficacy of Furosemide can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Fenbufen.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Furosemide.Approved
FenoprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Furosemide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Furosemide can be decreased when used in combination with Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Furosemide.Approved, Investigational
FloctafenineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluasteroneFluasterone may increase the hypokalemic activities of Furosemide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Furosemide.Approved, Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Furosemide.Approved, Investigational
FlunixinThe therapeutic efficacy of Furosemide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Furosemide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Furosemide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Furosemide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Furosemide.Approved, Investigational
FluprednideneFluprednidene may increase the hypokalemic activities of Furosemide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Furosemide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Furosemide.Approved
FlurbiprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneFluticasone may increase the hypokalemic activities of Furosemide.Approved, Experimental, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Furosemide.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Furosemide.Approved
FormestaneFormestane may increase the hypokalemic activities of Furosemide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
FoscarnetFurosemide may decrease the excretion rate of Foscarnet which could result in a higher serum level.Approved
FosinoprilFurosemide may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Furosemide.Approved, Investigational
FramycetinThe serum concentration of Framycetin can be increased when it is combined with Furosemide.Approved
GallamineFurosemide may decrease the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideFurosemide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe serum concentration of Geneticin can be increased when it is combined with Furosemide.Experimental
GentamicinThe serum concentration of Gentamicin can be increased when it is combined with Furosemide.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of GENTAMICIN C1A can be increased when it is combined with Furosemide.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Furosemide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Furosemide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Furosemide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Furosemide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Furosemide.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Furosemide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Furosemide.Approved
GuacetisalThe therapeutic efficacy of Furosemide can be decreased when used in combination with Guacetisal.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Furosemide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Furosemide.Investigational
HalcinonideHalcinonide may increase the hypokalemic activities of Furosemide.Approved, Investigational, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Furosemide.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Furosemide.Investigational
Hemoglobin crosfumarilThe therapeutic efficacy of Furosemide can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Furosemide.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Furosemide.Approved
HexoprenalineHexoprenaline may increase the hypokalemic activities of Furosemide.Approved, Withdrawn
HigenamineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Furosemide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Furosemide.Approved, Illicit
Hygromycin BThe serum concentration of Hygromycin B can be increased when it is combined with Furosemide.Vet Approved
IbuprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Furosemide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Furosemide can be decreased when used in combination with Icatibant.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Furosemide.Approved, Investigational
ImidaprilFurosemide may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Furosemide.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Furosemide.Approved
IndapamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Indapamide.Approved
IndobufenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Furosemide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Furosemide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Furosemide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Furosemide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Furosemide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Furosemide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Furosemide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Furosemide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Furosemide.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Irbesartan.Approved, Investigational
IsepamicinThe serum concentration of Isepamicin can be increased when it is combined with Furosemide.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Furosemide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Furosemide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Furosemide.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Furosemide.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Furosemide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Furosemide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide.Approved, Investigational
IstaroximeIstaroxime may increase the hypokalemic activities of Furosemide.Investigational
IvabradineFurosemide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe serum concentration of Kanamycin can be increased when it is combined with Furosemide.Approved, Investigational, Vet Approved
KebuzoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Kebuzone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Furosemide.Approved, Investigational
KetoprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Furosemide.Approved
LacidipineFurosemide may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Furosemide is combined with Lanatoside C.Experimental
LeflunomideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Furosemide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Furosemide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Furosemide.Approved, Investigational
LevodopaFurosemide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Furosemide.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Furosemide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Furosemide.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Furosemide.Approved, Investigational
LicoriceThe risk or severity of hypokalemia can be increased when Licorice is combined with Furosemide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Furosemide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Furosemide.Approved
LisinoprilFurosemide may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Furosemide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Furosemide.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Furosemide.Approved, Investigational
LonazolacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Furosemide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Furosemide.Approved
LoteprednolLoteprednol may increase the hypokalemic activities of Furosemide.Approved
LoxoprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Furosemide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Magnesium salicylate.Approved
MannitolThe risk or severity of adverse effects can be increased when Furosemide is combined with Mannitol.Approved, Investigational
MasoprocolThe therapeutic efficacy of Furosemide can be decreased when used in combination with Masoprocol.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Furosemide.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Furosemide is combined with Mecamylamine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Furosemide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Furosemide.Approved
Mefenamic acidThe therapeutic efficacy of Furosemide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Furosemide.Vet Approved
MeloxicamThe therapeutic efficacy of Furosemide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Furosemide.Experimental
MesalazineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Furosemide can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Furosemide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Furosemide.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Furosemide is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Furosemide.Approved
MethotrexateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Furosemide.Approved
Methyl salicylateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Furosemide is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Furosemide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Furosemide is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Furosemide is combined with Metipranolol.Approved
MetocurineFurosemide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideFurosemide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Furosemide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Furosemide.Approved, Investigational
MicronomicinThe serum concentration of Micronomicin can be increased when it is combined with Furosemide.Experimental
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Furosemide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Furosemide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Furosemide.Approved, Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Furosemide.Approved, Investigational
MivacuriumFurosemide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Mizoribine.Investigational
MoexiprilFurosemide may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Mofebutazone.Experimental
MometasoneMometasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Furosemide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Furosemide.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Furosemide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Furosemide can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Furosemide.Approved, Investigational
NabumetoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Furosemide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Furosemide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Furosemide.Approved
NaproxenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Furosemide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Furosemide.Investigational
NeamineThe serum concentration of Neamine can be increased when it is combined with Furosemide.Experimental
NebivololThe risk or severity of adverse effects can be increased when Furosemide is combined with Nebivolol.Approved, Investigational
NeomycinThe serum concentration of Neomycin can be increased when it is combined with Furosemide.Approved, Vet Approved
NeosaxitoxinFurosemide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nesiritide.Approved, Investigational
NetilmicinThe serum concentration of Netilmicin can be increased when it is combined with Furosemide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Furosemide.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Furosemide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Furosemide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Furosemide is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Furosemide can be decreased when used in combination with Niflumic Acid.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Furosemide.Approved, Investigational
NimesulideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Furosemide.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Furosemide.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Furosemide.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Furosemide.Approved
NitroaspirinThe therapeutic efficacy of Furosemide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Furosemide is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Furosemide.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Furosemide.Approved, Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Furosemide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Furosemide.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Furosemide.Approved, Investigational
OleandrinThe risk or severity of adverse effects can be increased when Furosemide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Furosemide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Furosemide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Furosemide.Approved
OlopatadineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatFurosemide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Furosemide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Furosemide.Approved
OrgoteinThe therapeutic efficacy of Furosemide can be decreased when used in combination with Orgotein.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Furosemide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Furosemide can be decreased when used in combination with Oxaprozin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Furosemide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Furosemide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furosemide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Furosemide.Approved, Vet Approved
PalmidrolThe therapeutic efficacy of Furosemide can be decreased when used in combination with Palmidrol.Experimental, Nutraceutical
PancuroniumFurosemide may decrease the neuromuscular blocking activities of Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Furosemide is combined with Papaverine.Approved, Investigational
ParamethasoneParamethasone may increase the hypokalemic activities of Furosemide.Approved
ParecoxibThe therapeutic efficacy of Furosemide can be decreased when used in combination with Parecoxib.Approved
ParomomycinThe serum concentration of Paromomycin can be increased when it is combined with Furosemide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Parthenolide.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Furosemide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Furosemide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Furosemide.Approved, Investigational, Vet Approved
PerindoprilFurosemide may increase the hypotensive activities of Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Furosemide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Furosemide.Approved
PF-00610355PF-00610355 may increase the hypokalemic activities of Furosemide.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Furosemide.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Furosemide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Furosemide.Approved, Investigational, Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Furosemide.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Furosemide.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Furosemide.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Furosemide.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Furosemide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Furosemide.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Furosemide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Furosemide is combined with Pindolol.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Furosemide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Furosemide.Approved, Investigational
PipecuroniumFurosemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Furosemide.Approved
PirfenidoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Furosemide.Approved, Investigational
PiroxicamThe therapeutic efficacy of Furosemide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Pirprofen.Experimental
PlazomicinThe serum concentration of Plazomicin can be increased when it is combined with Furosemide.Investigational
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Furosemide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Furosemide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Furosemide.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Furosemide.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Furosemide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Furosemide.Approved, Investigational
PrednisolonePrednisolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Furosemide.Approved, Experimental, Investigational
PrimidonePrimidone may increase the hypotensive activities of Furosemide.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Furosemide.Approved, Investigational
ProcaterolProcaterol may increase the hypokalemic activities of Furosemide.Approved, Investigational
ProglumetacinThe therapeutic efficacy of Furosemide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Furosemide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Furosemide.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Furosemide.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Furosemide is combined with Proscillaridin.Experimental
ProtokylolProtokylol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
PTC299The therapeutic efficacy of Furosemide can be decreased when used in combination with PTC299.Investigational
PuromycinThe serum concentration of Puromycin can be increased when it is combined with Furosemide.Experimental
PyrantelFurosemide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Furosemide is combined with Quetiapine.Approved
QuinaprilFurosemide may increase the hypotensive activities of Quinapril.Approved, Investigational
RacepinephrineRacepinephrine may increase the hypokalemic activities of Furosemide.Approved
RamiprilFurosemide may increase the hypotensive activities of Ramipril.Approved
RapacuroniumFurosemide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Furosemide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Furosemide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Furosemide.Approved, Investigational
RescinnamineFurosemide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Furosemide.Approved, Investigational
ResveratrolThe therapeutic efficacy of Furosemide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RibostamycinThe serum concentration of Ribostamycin can be increased when it is combined with Furosemide.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Furosemide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Furosemide is combined with Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Furosemide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Furosemide.Approved, Investigational
RocuroniumFurosemide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Furosemide can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Furosemide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Furosemide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Furosemide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Furosemide.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Furosemide.Approved
SalbutamolSalbutamol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Furosemide can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Furosemide.Approved
SalsalateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Salsalate.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Furosemide.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Furosemide.Approved, Investigational, Vet Approved
SemapimodThe therapeutic efficacy of Furosemide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Furosemide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Furosemide can be decreased when used in combination with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Furosemide.Approved, Vet Approved
SisomicinThe serum concentration of Sisomicin can be increased when it is combined with Furosemide.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Furosemide.Approved, Investigational
Sodium phosphateFurosemide may increase the nephrotoxic activities of Sodium phosphate.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Furosemide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Furosemide.Approved
SpiraprilFurosemide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Furosemide.Approved
SRT501The therapeutic efficacy of Furosemide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Furosemide.Approved, Investigational
StreptomycinThe serum concentration of Streptomycin can be increased when it is combined with Furosemide.Approved, Vet Approved
SuccinylcholineFurosemide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SucralfateThe serum concentration of Furosemide can be decreased when it is combined with Sucralfate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Furosemide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Furosemide can be decreased when used in combination with Sulindac.Approved, Investigational
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Furosemide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Furosemide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Furosemide can be decreased when used in combination with Suxibuzone.Experimental
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Furosemide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Furosemide.Approved
TarenflurbilThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Furosemide is combined with Telmisartan.Approved, Investigational
TemocaprilFurosemide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Furosemide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Furosemide.Approved
TeriflunomideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Furosemide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Furosemide.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Furosemide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Furosemide.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tiaprofenic acid.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Furosemide.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Furosemide.Approved
TinoridineThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tinoridine.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Furosemide.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Furosemide is combined with Tizanidine.Approved, Investigational
TobramycinThe serum concentration of Tobramycin can be increased when it is combined with Furosemide.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Furosemide.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Furosemide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Furosemide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Furosemide.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tolmetin.Approved
TopiramateThe risk or severity of hypokalemia can be increased when Furosemide is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Furosemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide.Approved, Investigational
TrandolaprilFurosemide may increase the hypotensive activities of Trandolapril.Approved
TranilastThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Furosemide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Furosemide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Furosemide.Approved
TribenosideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tribenoside.Experimental
TriptolideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Furosemide.Investigational, Withdrawn
Trolamine salicylateThe therapeutic efficacy of Furosemide can be decreased when used in combination with Trolamine salicylate.Approved
TubocurarineFurosemide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolUlobetasol may increase the hypokalemic activities of Furosemide.Approved
ValdecoxibThe therapeutic efficacy of Furosemide can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide.Approved, Investigational
VecuroniumFurosemide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Furosemide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Furosemide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Furosemide.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Furosemide.Approved, Investigational
ZaltoprofenThe therapeutic efficacy of Furosemide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Furosemide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilFurosemide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Furosemide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Increase potassium intake; add a banana or orange juice; unless instructed otherwise.
  • Take with food to reduce irritation.

References

Synthesis Reference

Angelo Signor, Alfredo Guerrato, Giovanni Signor, "Process for the preparation of furosemide." U.S. Patent US5739361, issued June, 1971.

US5739361
General References
  1. Rais-Bahrami K, Majd M, Veszelovszky E, Short BL: Use of furosemide and hearing loss in neonatal intensive care survivors. Am J Perinatol. 2004 Aug;21(6):329-32. [PubMed:15311369]
  2. Korpi ER, Kuner T, Seeburg PH, Luddens H: Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor. Mol Pharmacol. 1995 Feb;47(2):283-9. [PubMed:7870036]
  3. Tia S, Wang JF, Kotchabhakdi N, Vicini S: Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit. J Neurosci. 1996 Jun 1;16(11):3630-40. [PubMed:8642407]
  4. Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ: Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit. Mol Pharmacol. 1996 Sep;50(3):670-8. [PubMed:8794909]
External Links
Human Metabolome Database
HMDB0001933
KEGG Drug
D00331
KEGG Compound
C07017
PubChem Compound
3440
PubChem Substance
46506779
ChemSpider
3322
BindingDB
25902
ChEBI
47426
ChEMBL
CHEMBL35
Therapeutic Targets Database
DAP000043
PharmGKB
PA449719
HET
FUN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Furosemide
ATC Codes
C03EB01 — Furosemide and potassium-sparing agentsC03CB01 — Furosemide and potassiumC03CA01 — FurosemideG01AE10 — Combinations of sulfonamides
AHFS Codes
  • 40:28.08 — Loop Diuretics
PDB Entries
1z9y / 2xn5 / 3rf4
FDA label
Download (462 KB)
MSDS
Download (74.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentAcute Kidney Injury (AKI)1
0RecruitingPreventionTransfusion-associated Circulatory Overload1
1CompletedBasic ScienceDrug Drug Interactions1
1CompletedBasic ScienceDyspnea1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of Ipragliflozin1
1CompletedBasic ScienceRenal Hemodynamics1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentAcute Heart Failure (AHF)1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentRenal Failure1
1CompletedTreatmentType 2 Diabetes Mellitus1
1Not Yet RecruitingBasic ScienceMedication Absorption1
1Not Yet RecruitingTreatmentBody Weight Changes1
1RecruitingTreatmentCongestive Heart Failure (CHF) / Prophylaxis of cardiomyopathy1
1RecruitingTreatmentDifficulty Breathing1
1TerminatedTreatmentHeart Failure, Unspecified / Impaired Renal Function1
1, 2Active Not RecruitingBasic ScienceDyspnea / Healthy Volunteers1
1, 2CompletedSupportive CareDyspnea1
1, 2CompletedTreatmentHeart Failure, Unspecified1
1, 2CompletedTreatmentHeart Failure, Unspecified / Renal Function Abnormal1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2WithdrawnTreatmentAcute Decompensated Heart Failure (ADHF)1
2CompletedSupportive CarePulmonary Complications1
2CompletedTreatmentAscites / Liver Cirrhosis1
2CompletedTreatmentBronchiolitis1
2CompletedTreatmentCutaneous Warts1
2CompletedTreatmentHeart Failure, Unspecified1
2CompletedTreatmentTransient Tachypnoea of the Newborn1
2RecruitingOtherChronic Lung Disease of Prematurity1
2RecruitingPreventionHigh Blood Pressure (Hypertension)1
2RecruitingTreatmentAcute Heart Failure (AHF) / Decompensated Heart Failure1
2RecruitingTreatmentPolyps, Nasal1
2WithdrawnTreatmentDelayed Graft Function1
2, 3CompletedTreatmentCongestive Heart Failure (CHF)1
2, 3CompletedTreatmentHeart Failure, Unspecified2
2, 3RecruitingHealth Services ResearchAcute Heart Failure (AHF)1
2, 3TerminatedTreatmentAcute Renal Failure (ARF)1
3Active Not RecruitingTreatmentCutaneous Common Warts1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
3CompletedSupportive CareBronchiolitis1
3CompletedTreatmentCongestive Heart Failure (CHF) / Impaired Renal Function1
3CompletedTreatmentFluid Overload1
3CompletedTreatmentHypertension,Essential / Impaired Renal Function1
3CompletedTreatmentTransient Tachypnea of the Newborn1
3Not Yet RecruitingTreatmentAcute Myocardial Infarction With Right Ventricular Extension1
3Not Yet RecruitingTreatmentHeart Failure, Unspecified1
3RecruitingDiagnosticChronic Kidney Disease (CKD)1
3RecruitingTreatmentFluid Balance of ICU Patients / Fluid Overload1
3RecruitingTreatmentHeart Failure, Unspecified1
3SuspendedTreatmentCongestive Heart Failure (CHF)1
3TerminatedTreatmentCritically Ill / Renal Failure1
3Unknown StatusPreventionContrast Induced Nephropathy (CIN)1
3Unknown StatusTreatmentChronic Lung Diseases1
3WithdrawnTreatmentHeart Failure, Unspecified1
3WithdrawnTreatmentRenal Function Disorder1
4Active Not RecruitingTreatmentHeart Failure, Diastolic1
4CompletedPreventionArterial Hypotension / Congestive Heart Failure (CHF) / Edema / High Blood Pressure (Hypertension)1
4CompletedTreatmentAcute Decompensated Heart Failure (ADHF)1
4CompletedTreatmentAcute Heart Failure (AHF)1
4CompletedTreatmentAscites / Liver Cirrhosis2
4CompletedTreatmentChronic Heart Failure (CHF) / Congestive Heart Failure (CHF)1
4CompletedTreatmentChronic Kidney Disease (CKD)1
4CompletedTreatmentChronic Stable Heart Failure2
4CompletedTreatmentColorectal Disorders1
4CompletedTreatmentCongestive Heart Failure (CHF)2
4CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
4CompletedTreatmentEdema / Glomerulonephritis minimal lesion1
4CompletedTreatmentPreeclampsia1
4Not Yet RecruitingOtherCystoscopy1
4Not Yet RecruitingTreatmentAcute Heart Failure (AHF)1
4RecruitingDiagnosticEnd Stage Renal Disease (ESRD)1
4RecruitingTreatmentHeart Failure, Unspecified2
4RecruitingTreatmentHypertension Resistant To Conventional Therapy1
4RecruitingTreatmentProteinuria / Renal Insufficiency,Chronic1
4RecruitingTreatmentPulmonary Embolism (PE)1
4TerminatedTreatmentAcute Decompensated Heart Failure (ADHF)1
4TerminatedTreatmentAcute Kidney Injury (AKI) / Critical Illness / Fluid Overload1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusTreatmentAcute Heart Failure (AHF)1
4Unknown StatusTreatmentChronic Kidney Insufficiency / Diuresis Preserved / Hemodialysis Treatment1
4Unknown StatusTreatmentHealthy Male and Female Volunteers1
4WithdrawnTreatmentKidney Failures, Acute1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableCompletedDiagnosticCardiorenal Syndrome1
Not AvailableCompletedDiagnosticChronic Kidney Disease (CKD)1
Not AvailableCompletedPreventionAcute Renal Failure (ARF)1
Not AvailableCompletedTreatmentAcromegaly1
Not AvailableCompletedTreatmentAcute Kidney Injury (AKI)1
Not AvailableCompletedTreatmentFluid Over-load1
Not AvailableCompletedTreatmentNeoplasms, Brain1
Not AvailableCompletedTreatmentRenal Stones1
Not AvailableNot Yet RecruitingTreatmentHeart Decompensation1
Not AvailableRecruitingNot AvailableAcidosis, Renal Tubular / Calcium Nephrolithiasis / Vacuolar Proton-Translocating ATPases1
Not AvailableRecruitingDiagnosticAcute Renal Failure (ARF)1
Not AvailableRecruitingDiagnosticCritical Illness / Oliguria1
Not AvailableRecruitingDiagnosticDelayed Graft Function / Kidney Function / Kidney Transplant; Complications1
Not AvailableRecruitingPreventionChronic Kidney Disease (CKD) / Hyperparathyroidism, Secondary1
Not AvailableRecruitingTreatmentCritical Care / Fluid Shifts1
Not AvailableRecruitingTreatmentHeart Failure, Unspecified1
Not AvailableTerminatedDiagnosticAcute Decompensated Heart Failure (ADHF)1
Not AvailableTerminatedTreatmentAcute Decompensated Heart Failure (ADHF) / Cardiac Failure / Heart Failure, Unspecified1
Not AvailableTerminatedTreatmentBrain Swelling / Dehydration1
Not AvailableTerminatedTreatmentObesity-induced Hyperfiltration1
Not AvailableUnknown StatusNot AvailableHeart Failure, Unspecified1
Not AvailableUnknown StatusTreatmentHypernatremia / Respiratory Failure / Volume Overload1
Not AvailableUnknown StatusTreatmentIntra-Abdominal Hypertension1
Not AvailableWithdrawnPreventionRenal Impairment After Cardiac Surgery1
Not AvailableWithdrawnTreatmentAnemia Treatment Among Patients Suffering From Left Ventricular Systolic Dysfunction1
Not AvailableWithdrawnTreatmentCongestive Heart Failure (CHF)2
Not AvailableWithdrawnTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Organon usa inc
  • Smith and nephew solopak div smith and nephew
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Wockhardt ltd
  • Wyeth ayerst laboratories
  • Sanofi aventis us llc
  • Roxane laboratories inc
  • Wockhardt eu operations (swiss) ag
  • Dava pharmaceuticals inc
  • Excellium pharmaceutical inc
  • International medication systems ltd
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kalapharm inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Superpharm corp
  • Vintage pharmaceuticals inc
  • County line pharmaceuticals llc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • American Regent
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Bryant Ranch Prepack
  • C.O. Truxton Inc.
  • Cardinal Health
  • Central Texas Community Health Centers
  • Comprehensive Consultant Services Inc.
  • Coupler Enterprises Inc.
  • CVS Pharmacy
  • DAVA Pharmaceuticals
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Excellium Pharmaceutical Inc.
  • General Injectables and Vaccines Inc.
  • Goldline Laboratories Inc.
  • Group Health Cooperative
  • H and H Laboratories
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Intervet International
  • Ipca Laboratories Ltd.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Luitpold Pharmaceuticals Inc.
  • Macnary Ltd.
  • Major Pharmaceuticals
  • Mason Distributors
  • Mckesson Corp.
  • Medvantx Inc.
  • Merrell Pharmaceuticals Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neighborcare Repackaging Inc.
  • Neuman Distributors Inc.
  • Norwich Pharmaceuticals Inc.
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Sandoz
  • Sanofi-Aventis Inc.
  • Southwood Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Stat Scripts LLC
  • Talbert Medical Management Corp.
  • Taylor Pharmaceuticals
  • Tya Pharmaceuticals
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Vatring Pharmaceuticals
  • Vedco Inc.
  • Vintage Pharmaceuticals Inc.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
TabletOral20 mg
TabletOral40 mg
Kit
InjectionIntramuscular; Intravenous10 mg/2mL
InjectionIntramuscular; Intravenous10 mg/mL
InjectionIntramuscular; Intravenous100 mg/10mL
InjectionIntramuscular; Intravenous20 mg/2mL
InjectionIntramuscular; Intravenous40 mg/4mL
InjectionIntravenous10 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntravenous10 mg/mL
SolutionOral10 mg/mL
SolutionOral40 mg/4mL
SolutionOral40 mg/5mL
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
LiquidIntramuscular; Intravenous10 mg
SolutionIntramuscular; Intravenous10 mg
SolutionIntramuscular; Intravenous20 mg
SolutionIntravenous250 mg
LiquidIntravenous250 mg
SolutionIntravenous10 mg
TabletOral80 mg
LiquidOral10 mg
SolutionOral10 mg
LiquidIntramuscular; Intravenous20 mg
TabletOral500 mg
LiquidIntravenous10 mg
Prices
Unit descriptionCostUnit
Hydro 40 40% Foam 150 gm Can182.52USD can
Hydro 40 40% Foam 70 gm Can148.99USD can
Furosemide 10 mg/ml Solution 60ml Bottle17.99USD bottle
Furosemide 10 mg/ml Solution 120ml Bottle15.98USD bottle
Furosemide powder3.51USD g
Lasix Special 500 mg Tablet3.25USD tablet
Urex 1 gm tablet2.47USD tablet
Furosemide 10 mg/ml cartrg1.45USD ml
Lasix 80 mg tablet1.0USD tablet
Furosemide 10 mg/ml Solution0.9USD ml
Furosemide 10 mg/ml0.75USD ml
Lasix 40 mg tablet0.53USD tablet
Furosemide 80 mg tablet0.45USD tablet
Lasix 20 mg tablet0.42USD tablet
Lasix 10 mg/ml Solution0.3USD ml
CVS Pharmacy diuretic 50 mg softgel0.17USD softgel capsule
Furosemide 40 mg tablet0.16USD tablet
Furosemide 20 mg tablet0.14USD tablet
Apo-Furosemide 80 mg Tablet0.13USD tablet
Novo-Semide 80 mg Tablet0.13USD tablet
Nat herbal diuretic tablet sa0.1USD tablet
Apo-Furosemide 40 mg Tablet0.07USD tablet
Natural herbal diuretic tablet0.07USD tablet
Novo-Semide 40 mg Tablet0.07USD tablet
Apo-Furosemide 20 mg Tablet0.05USD tablet
Novo-Semide 20 mg Tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)206U.S. Patent 3,058,882.
water solubility73.1 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.03SANGSTER (1993)
logS-3.66ADME Research, USCD
Caco2 permeability-6.5ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.118 mg/mLALOGPS
logP2.71ALOGPS
logP1.75ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.25ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area122.63 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity77.47 m3·mol-1ChemAxon
Polarizability30.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9155
Blood Brain Barrier-0.8833
Caco-2 permeable-0.6436
P-glycoprotein substrateNon-substrate0.8775
P-glycoprotein inhibitor INon-inhibitor0.9272
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.924
CYP450 2C9 substrateNon-substrate0.6878
CYP450 2D6 substrateNon-substrate0.8351
CYP450 3A4 substrateNon-substrate0.6789
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9602
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6885
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6469
BiodegradationNot ready biodegradable0.9881
Rat acute toxicity2.1362 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9342
hERG inhibition (predictor II)Non-inhibitor0.8525
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-03dr-0090000000-da505a3f09285d049f34
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-0f89-2190000000-53c91100e89c81f0fa30
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-01ox-9660000000-83d8486cbca0dd3487c9
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-f3a3dcb92cfcdff9f7dc
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0019000000-946089b12d2ab6fd05a4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-04af1dec204d462d4bc4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1090000000-1af70d23e1a0ebaa0878
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9770000000-0c5cd578b5b69a1a61d4
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9800000000-3303b20f9b23e24ae312
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9400000000-23cfec716ac8fbcb092f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0019000000-e73aa1d969ab4255732b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-33053544119c01ac6b45
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1090000000-7029ab63efa73a3ff88d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9670000000-4bad8928bbcfc85f431f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9800000000-2193e38e314f2b18be26
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9600000000-e703f7ab6221182df156
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-f3645e993869ff3886ba
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-18400153a811f7100a2f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0f79-0090000000-7e491b92dab050fb81c0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-8e41d38fe799d96230a6
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-cfec4a54171c58245919
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0ug0-0193000000-b55039ca13cbc3acd9a8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0290000000-1f1017fe4370d9541f6d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-9110000000-505f1e781d384073f688
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001j-9000000000-cd886e0521fb4d1bdc82
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-8a69e99643ee37bc1883
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-f7ac3c9eea39ed725cfc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-8a294fd51a34073aa4a1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-b16e204dec9ae7938d40
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f8a-9220000000-3bde836fe7e67c9b8755
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-9025c2261c96ca3aa551
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-9000000000-8d05f828403d0fe7cac4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-3cd4f8015eb5fafacacb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-34937031271e62c39c1f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-9000000000-40e9966d335f71aedb96
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0290000000-586707fb0116e8b61643
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-9000000000-f6727b05eb8ee02a6e7c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-51662bec1d461d0f0a5a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-8eea44e0dd27bb59939d
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Aminobenzenesulfonamides
Alternative Parents
4-halobenzoic acids / Aminobenzoic acids / Halobenzoic acids / Benzenesulfonyl compounds / Benzoic acids / Aniline and substituted anilines / Benzoyl derivatives / Phenylalkylamines / Secondary alkylarylamines / Chlorobenzenes
show 15 more
Substituents
Aminobenzenesulfonamide / 4-halobenzoic acid or derivatives / Aminobenzoic acid / Aminobenzoic acid or derivatives / Halobenzoic acid or derivatives / 4-halobenzoic acid / Halobenzoic acid / Benzenesulfonyl group / Benzoic acid / Benzoic acid or derivatives
show 37 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, furans, chlorobenzoic acid (CHEBI:47426)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Brater DC: Pharmacology of diuretics. Am J Med Sci. 2000 Jan;319(1):38-50. [PubMed:10653443]
  2. Davies DL, Wilson GM: Diuretics: mechanism of action and clinical application. Drugs. 1975;9(3):178-226. [PubMed:1092541]
  3. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function
Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name
PGD
Uniprot ID
P52209
Uniprot Name
6-phosphogluconate dehydrogenase, decarboxylating
Molecular Weight
53139.56 Da
References
  1. Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Lebedev AA, Samokrutova OV: [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence]. Farmakol Toksikol. 1989 May-Jun;52(3):40-3. [PubMed:2792351]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Kim GH, Na KY, Kim SY, Joo KW, Oh YK, Chae SW, Endou H, Han JS: Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney. Nephrol Dial Transplant. 2003 Aug;18(8):1505-11. [PubMed:12897087]
  2. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [PubMed:9887087]
  3. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961]
  4. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, a...
Gene Name
SLCO2A1
Uniprot ID
Q92959
Uniprot Name
Solute carrier organic anion transporter family member 2A1
Molecular Weight
70043.33 Da
References
  1. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. [PubMed:7754369]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]

Drug created on June 13, 2005 07:24 / Updated on June 18, 2018 06:30